Literature DB >> 24124816

Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States.

Sarah Sung1, Alexa B Kimball2.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24124816     DOI： 10.1016/j.jaad.2013.06.043

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

1.  The validity of the diagnostic code for hidradenitis suppurativa in an electronic database.

Authors:  G E Kim; J Shlyankevich; A B Kimball
Journal:  Br J Dermatol       Date:  2014-07-26       Impact factor: 9.302

2.  Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012.

Authors:  Kathleen McMillan
Journal:  Skin Appendage Disord       Date:  2015-09-18

Review 3.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

4.  Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases.

Authors:  Alexandros C Katoulis; Aikaterini I Liakou; Nikolaos Rotsiamis; Stefanos Bonovas; Evangelia Bozi; Efstathios Rallis; Christos Christodoulou; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2017-05-17

5.  Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data.

Authors:  Jessica Marvel; Anna Vlahiotis; Amy Sainski-Nguyen; Tina Willson; Alexandra Kimball
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

6.  New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities.

Authors:  Lisette M Prens; Klasiena Bouwman; Lisa D Troelstra; Errol P Prens; Behrooz Z Alizadeh; Barbara Horváth
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

7.  Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Authors:  Nobukazu Hayashi; Koremasa Hayama; Kenzo Takahashi; Ichiro Kurokawa; Masateru Okazaki; Tomoko Kashiwagi; Eri Iwashita; Tadashi Terui
Journal:  J Dermatol       Date:  2022-01-17       Impact factor: 3.468
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.